Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

NKTR-214: Harnessing the IL-2 Pathway in Combination Immunotherapies

  • Broadcast in Science
Pharma Talk Radio

Pharma Talk Radio

Featured Host
×  

Follow This Show

If you liked this show, you should follow Pharma Talk Radio.
h:548881
s:11690824
archived
Play
  • Host

In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Willem Overwijk, Nektar Therapeutics discusses Bempegaldesleukin (NKTR-214): harnessing the IL-2 pathway in combination immunotherapies. Topics include:

  • Bempegaldesleukin: Structure and function of an engineered IL-2 cytokine prodrug providing sustained IL-2Rβγ-biased signaling
  • Preclinical PK, PD, MOA and combination with PD-1 checkpoint inhibition
  • Clinical PK, PD, clinical response data and biomarkers in patients with melanoma and bladder cancer
  • Combinations under investigation

To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled